Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572065 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis
A Early Phase 1 study of Myelofibrosis, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00572065 is a Early Phase 1 study of Myelofibrosis that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 21 participants, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00572065, a Early Phase 1 study of Myelofibrosis, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, one arm, single institution study. Arsenic trioxide \[TrisenoxTM Injection\], 0.25mg/kg/dose administered intravenously over 2 hours. 20 patients Complete remission, partial remission, clinical improvement, progressive disease, stable disease, relapse (per IWG consensus criteria, 2006) Clinical chemistry, hematology and ECGs will be assessed at least weekly during study treatments. Adverse events will be assessed in accordance with the NCI Common Toxicity Criteria, Version 2 at each study visit.
Conditions Studied
Interventions
- DRUG cytarabine
- DRUG arsenic trioxide
Study Locations (1)
New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-02-29 |
| Est. Completion | 2010-02-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572065
The ClinicalTrials.gov registry entry for NCT00572065 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (89% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which cytarabine is the first listed.
NCT00572065 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00572065 about?
NCT00572065 is a clinical study titled "Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis". This is an open-label, one arm, single institution study. Arsenic trioxide \[TrisenoxTM Injection\], 0.25mg/kg/dose administered intravenously over 2 hours. 20 patients Complete remission, partial remission, clinical improvement, progressive disease, stable disease, relapse (per IWG consensus crit...
What is the current status of trial NCT00572065?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2008-02-29. Estimated completion is 2010-02-08.
What conditions does trial NCT00572065 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT00572065?
The interventions under investigation include: cytarabine (DRUG), arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00572065?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572065 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
RECRUITING · Early Phase 1
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 3
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.